Right Heart Involvement in Hepatic Diseases

  • Ana-Maria Vintilă
  • Monica Dobrovie
  • Vlad Damian Vintilă


It is well known there is a relationship between the heart and the liver. A significant proportion of patients with heart failure have suffered at some point from congestive hepatopathy or developed ischemic hepatitis in acute situations. The aim of this chapter is to raise awareness about another situation involving the liver and the heart: patients with primary liver disease that affects the heart. It is a very interesting field, with lots of unknowns, but which deserves our attention as liver disease is prevalent amongst patients worldwide.

In the first part, we will briefly explain the pathophysiology of portal hypertension (PoH), and its systemic consequences that influence heart function. Then, we will focus on three relevant clinical pathologies: cirrhotic cardiomyopathy (CCM), portopulmonary hypertension (PoPH) and hepatopulmonary syndrome (HPS). In the end we will briefly mention other liver disease that may affect the right heart.


Portal hypertension Cirrhotic cardiomyopathy Portopulmonary hypertension Hepatopulmonary syndrome 


  1. 1.
    Berzigotti A, Seijo S, Reverter E, Bosch J. Assessing portal hypertension in liver diseases. Expert Rev Gastroenterol Hepatol. 2013;7(2):141–55.CrossRefPubMedGoogle Scholar
  2. 2.
    Schouten JN, Garcia-Pagan JC, Valla DC, Janssen HL. Idiopathic noncirrhotic portal hypertension. Hepatology. 2011;54(3):1071–81.CrossRefPubMedGoogle Scholar
  3. 3.
    Rockey DC. Cell and molecular mechanisms of increased intrahepatic resistance and hemodynamic correlates. In: Portal hypertension. Berlin: Springer; 2005. p. 37–50.CrossRefGoogle Scholar
  4. 4.
    Reynaert H, Thompson M, Thomas T, Geerts A. Hepatic stellate cells: role in microcirculation and pathophysiology of portal hypertension. Gut. 2002;50(4):571–81.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Pinzani M, Milani S, De Franco R, Grappone C, Caligiuri A, Gentilini A, et al. Endothelin 1 is overexpressed in human cirrhotic liver and exerts multiple effects on activated hepatic stellate cells. Gastroenterology. 1996;110(2):534–48.CrossRefPubMedGoogle Scholar
  6. 6.
    Gracia-Sancho J, Lavina B, Rodríguez-Vilarrupla A, García-Calderó H, Fernández M, Bosch J, et al. Increased oxidative stress in cirrhotic rat livers: a potential mechanism contributing to reduced nitric oxide bioavailability. Hepatology. 2008;47(4):1248–56.CrossRefPubMedGoogle Scholar
  7. 7.
    Shah V, Toruner M, Haddad F, Cadelina G, Papapetropoulos A, Choo K, et al. Impaired endothelial nitric oxide synthase activity associated with enhanced caveolin binding in experimental cirrhosis in the rat. Gastroenterology. 1999;117(5):1222–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Toubia N, Sanyal AJ. Portal hypertension and variceal hemorrhage. Med Clin North Am. 2008;92(3):551–74.CrossRefPubMedGoogle Scholar
  9. 9.
    Feldman M, Friedman LS, Brandt LJ. Sleisenger and Fordtran’s gastrointestinal and liver disease E-book: pathophysiology, diagnosis, management, expert consult premium edition-enhanced online features, vol. 1. Amsterdam: Elsevier; 2010.Google Scholar
  10. 10.
    Sieber CC, Sumanovski LT, Stumm M, van der Kooij M, Battegay E. In vivo angiogenesis in normal and portal hypertensive rats: role of basic fibroblast growth factor and nitric oxide. J Hepatol. 2001;34(5):644–50.CrossRefPubMedGoogle Scholar
  11. 11.
    Fernandez M, Mejias M, Angermayr B, Garcia-Pagan JC, Rodés J, Bosch J. Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats. J Hepatol. 2005;43(1):98–103.CrossRefPubMedGoogle Scholar
  12. 12.
    Van Steenkiste C, Geerts A, Vanheule E, Van Vlierberghe H, De Vos F, Olievier K, et al. Role of placental growth factor in mesenteric neoangiogenesis in a mouse model of portal hypertension. Gastroenterology. 2009;137(6):2112–24. e2116.CrossRefPubMedGoogle Scholar
  13. 13.
    Coll M, Martell M, Raurell I, Ezkurdia N, Cuenca S, Hernández-Losa J, et al. Atrophy of mesenteric sympathetic innervation may contribute to splanchnic vasodilation in rat portal hypertension. Liver Int. 2010;30(4):593–602.CrossRefPubMedGoogle Scholar
  14. 14.
    Ezkurdia N, Coll M, Raurell I, Rodriguez S, Cuenca S, González A, et al. Blockage of the afferent sensitive pathway prevents sympathetic atrophy and hemodynamic alterations in rat portal hypertension. Liver Int. 2012;32(8):1295–305.CrossRefPubMedGoogle Scholar
  15. 15.
    Møller S, Bendtsen F, Henriksen JH. Effect of volume expansion on systemic hemodynamics and central and arterial blood volume in cirrhosis. Gastroenterology. 1995;109(6):1917–25.CrossRefPubMedGoogle Scholar
  16. 16.
    Salerno F, Gerbes A, Ginès P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Postgrad Med J. 2008;84(998):662–70.CrossRefPubMedGoogle Scholar
  17. 17.
    Mocarzel LOC, Rossi MM, BdM M, Lanzieri PG, Gismondi RA. Cirrhotic cardiomyopathy: a new clinical phenotype. Arq Bras Cardiol. 2017;108(6):564–8.PubMedPubMedCentralGoogle Scholar
  18. 18.
    Enache I, Oswald-Mammosser M, Woehl-Jaegle M-L, Habersetzer F, Di Marco P, Charloux A, et al. Cirrhotic cardiomyopathy and hepatopulmonary syndrome: prevalence and prognosis in a series of patients. Respir Med. 2013;107(7):1030–6.CrossRefPubMedGoogle Scholar
  19. 19.
    Lotterer E, Wengert A, Fleig WE. Transjugular intrahepatic portosystemic shunt: short-term and long-term effects on hepatic and systemic hemodynamics in patients with cirrhosis. Hepatology. 1999;29(3):632–9.CrossRefPubMedGoogle Scholar
  20. 20.
    Fouad TR, Abdel-Razek WM, Burak KW, Bain VG, Lee SS. Prediction of cardiac complications after liver transplantation. Transplantation. 2009;87(5):763–70.CrossRefPubMedGoogle Scholar
  21. 21.
    Vogt DP, Henderson JM, Carey WD, Barnes D. The long-term survival and causes of death in patients who survive at least 1 year after liver transplantation. Surgery. 2002;132(4):775–80.CrossRefPubMedGoogle Scholar
  22. 22.
    Kia L, Shah S, Wang E, Sharma D, Selvaraj S, Medina C, et al. Role of pretransplant echocardiographic evaluation in predicting outcomes following liver transplantation. Am J Transplant. 2013;13(9):2395–401.CrossRefGoogle Scholar
  23. 23.
    Le Pavec J, Humbert M, Hervé P, Simonneau G, Sitbon O. Screening for portopulmonary hypertension with transthoracic echocardiography: implications for early mortality associated with liver transplantation. Am J Respir Crit Care Med. 2009;180(4):378–9.CrossRefGoogle Scholar
  24. 24.
    Naqvi IH, Mahmood K, Naeem M, Vashwani AS, Ziaullah S. The heart matters when the liver shatters! Cirrhotic cardiomyopathy: frequency, comparison, and correlation with severity of disease. Prz Gastroenterol. 2016;11(4):247.PubMedPubMedCentralGoogle Scholar
  25. 25.
    Shaikh S, Abro M, Qazi I, Yousfani A. Frequency of cirrhotic cardiomyopathy in patients with cirrhosis of liver: a tertiary care hospital experience. Pak J Med Sci. 2011;27(4):744–8.Google Scholar
  26. 26.
    Kazankov K, Holland-Fischer P, Andersen NH, Torp P, Sloth E, Aagaard NK, et al. Resting myocardial dysfunction in cirrhosis quantified by tissue Doppler imaging. Liver Int. 2011;31(4):534–40.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Chen Y, Chan AC, Chan S-C, Chok S-H, Sharr W, Fung J, et al. A detailed evaluation of cardiac function in cirrhotic patients and its alteration with or without liver transplantation. J Cardiol. 2016;67(2):140–6.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Ma Z, Miyamoto A, Lee SS. Role of altered beta-adrenoceptor signal transduction in the pathogenesis of cirrhotic cardiomyopathy in rats. Gastroenterology. 1996;110(4):1191–8.CrossRefPubMedGoogle Scholar
  29. 29.
    Wong F, Villamil A, Merli M, Romero G, Angeli P, Caraceni P, et al. Prevalence of diastolic dysfunction in cirrhosis, and its clinical significance. Hepatology. 2011;54(4):475A–6A.CrossRefGoogle Scholar
  30. 30.
    Heuer A, Gehl A, Püschel K, Sydow K, Lohse A, Lüth S. 160 high rate of cardiac abnormalities in a post-mortem analysis of patients suffering from liver cirrhosis. J Hepatol. 2011;54:S69.CrossRefGoogle Scholar
  31. 31.
    Bernardi M, Calandra S, Colantoni A, Trevisani F, Raimondo ML, Sica G, et al. Q-T interval prolongation in cirrhosis: prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors. Hepatology. 1998;27(1):28–34.CrossRefPubMedGoogle Scholar
  32. 32.
    Trevisani F, Merli M, Savelli F, Valeriano V, Zambruni A, Riggio O, et al. QT interval in patients with non-cirrhotic portal hypertension and in cirrhotic patients treated with transjugular intrahepatic porto-systemic shunt. J Hepatol. 2003;38(4):461–7.CrossRefPubMedGoogle Scholar
  33. 33.
    Ytting H, Henriksen JH, Fuglsang S, Bendtsen F, Møller S. Prolonged Q–T c interval in mild portal hypertensive cirrhosis. J Hepatol. 2005;43(4):637–44.CrossRefPubMedGoogle Scholar
  34. 34.
    Zambruni A, Di Micoli A, Lubisco A, Domenicali M, Trevisani F, Bernardi M. QT interval correction in patients with cirrhosis. J Cardiovasc Electrophysiol. 2007;18(1):77–82.CrossRefPubMedGoogle Scholar
  35. 35.
    Bernardi M, Trevisani F, De Palma R, Ligabue A, Capani F, Baraldini M, et al. Chronobiological evaluation of sympathoadrenergic function in cirrhosis: relationship with arterial pressure and heart rate. Gastroenterology. 1987;93(6):1178–86.CrossRefPubMedGoogle Scholar
  36. 36.
    Ramond M, Comoy E, Lebrec D. Alterations in isoprenaline sensitivity in patients with cirrhosis: evidence of abnormality of the sympathetic nervous activity. Br J Clin Pharmacol. 1986;21(2):191–6.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Pateron D, Beyne P, Laperche T, Logeard D, Lefilliatre P, Sogni P, et al. Elevated circulating cardiac troponin I in patients with cirrhosis. Hepatology. 1999;29(3):640–3.CrossRefPubMedGoogle Scholar
  38. 38.
    Licata A, Corrao S, Petta S, Genco C, Cardillo M, Calvaruso V, et al. NT pro BNP plasma level and atrial volume are linked to the severity of liver cirrhosis. PLoS One. 2013;8(8):e68364.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Møller S, Henriksen JH. Cardiovascular complications of cirrhosis. Postgrad Med J. 2009;85(999):44–54.PubMedGoogle Scholar
  40. 40.
    Pozzi M, Grassi G, Ratti L, Favini G, Dell’Oro R, Redaelli E, et al. Cardiac, neuroadrenergic, and portal hemodynamic effects of prolonged aldosterone blockade in postviral child a cirrhosis. Am J Gastroenterol. 2005;100(5):1110.CrossRefPubMedGoogle Scholar
  41. 41.
    Henriksen JH, Bendtsen F, Hansen EF, Møller S. Acute non-selective β-adrenergic blockade reduces prolonged frequency-adjusted Q–T interval (QT c) in patients with cirrhosis. Gan To Kagaku Ryoho. 2004;40(2):239–46.Google Scholar
  42. 42.
    Zambruni A, Trevisani F, Di Micoli A, Savelli F, Berzigotti A, Bracci E, et al. Effect of chronic β-blockade on QT interval in patients with liver cirrhosis. J Hepatol. 2008;48(3):415–21.CrossRefPubMedGoogle Scholar
  43. 43.
    Torregrosa M, Aguadé S, Dos L, Segura R, Gónzalez A, Evangelista A, et al. Cardiac alterations in cirrhosis: reversibility after liver transplantation. J Hepatol. 2005;42(1):68–74.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Benjaminov F, Prentice M, Sniderman K, Siu S, Liu P, Wong F. Portopulmonary hypertension in decompensated cirrhosis with refractory ascites. Gut. 2003;52(9):1355–62.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Hoeper M, Halank M, Marx C, Hoeffken G, Seyfarth H, Schauer J, et al. Bosentan therapy for portopulmonary hypertension. Eur Respir J. 2005;25(3):502–8.CrossRefPubMedGoogle Scholar
  46. 46.
    Nunes H, Lebrec D, Mazmanian M, Capron F, Heller J, Tazi KA, et al. Role of nitric oxide in hepatopulmonary syndrome in cirrhotic rats. Am J Respir Crit Care Med. 2001;164(5):879–85.CrossRefPubMedGoogle Scholar
  47. 47.
    Thenappan T, Goel A, Marsboom G, Fang Y-H, Toth PT, Zhang HJ, et al. A central role for CD68 (+) macrophages in hepatopulmonary syndrome: reversal by macrophage depletion. Am J Respir Crit Care Med. 2011;183(8):1080–91.CrossRefPubMedGoogle Scholar
  48. 48.
    Zhang J, Yang W, Luo B, Hu B, Maheshwari A, Fallon MB. The role of CX 3 CL1/CX 3 CR1 in pulmonary angiogenesis and intravascular monocyte accumulation in rat experimental hepatopulmonary syndrome. J Hepatol. 2012;57(4):752–8.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Liu L, Liu N, Zhao Z, Liu J, Feng Y, Jiang H, et al. TNF-α neutralization improves experimental hepatopulmonary syndrome in rats. Liver Int. 2012;32(6):1018–26.CrossRefPubMedGoogle Scholar
  50. 50.
    Rabiller A, Nunes H, Lebrec D, Tazi KA, Wartski M, Dulmet E, et al. Prevention of gram-negative translocation reduces the severity of hepatopulmonary syndrome. Am J Respir Crit Care Med. 2002;166(4):514–7.CrossRefPubMedGoogle Scholar
  51. 51.
    Galiè N, Humbert M, Vachiery J-L, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2015;37(1):67–119.CrossRefPubMedGoogle Scholar
  52. 52.
    Rodriguez-Roisin R, Krowka MJ, Herve P, Fallon M. Pulmonary–hepatic vascular disorders (PHD). Eur Respir J. 2004;24(5):861–80.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Kawut SM, Krowka MJ, Trotter JF, Roberts KE, Benza RL, Badesch DB, et al. Clinical risk factors for portopulmonary hypertension. Hepatology. 2008;48(1):196–203.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Regev A, Yeshurun M, Rodriguez M, Sagie A, Neff G, Molina E, et al. Transient hepatopulmonary syndrome in a patient with acute hepatitis a. J Viral Hepat. 2001;8(1):83–6.CrossRefPubMedGoogle Scholar
  55. 55.
    Fuhrmann V, Madl C, Mueller C, Holzinger U, Kitzberger R, Funk GC, et al. Hepatopulmonary syndrome in patients with hypoxic hepatitis. Gastroenterology. 2006;131(1):69–75.CrossRefPubMedGoogle Scholar
  56. 56.
    Krowka MJ, Swanson KL, Frantz RP, McGoon MD, Wiesner RH. Portopulmonary hypertension: results from a 10-year screening algorithm. Hepatology. 2006;44(6):1502–10.CrossRefPubMedGoogle Scholar
  57. 57.
    Grannas G, Neipp M, Hoeper MM, Gottlieb J, Lück R, Becker T, et al. Indications for and outcomes after combined lung and liver transplantation: a single-center experience on 13 consecutive cases. Transplantation. 2008;85(4):524–31.CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Porres-Aguilar M. Emphasizing the importance of the clinical classification for pulmonary hypertension. Ann Hepatol. 2009;8(3):267–8.PubMedGoogle Scholar
  59. 59.
    Garg A, Armstrong WF. Echocardiography in liver transplant candidates. JACC Cardiovasc Imaging. 2013;6(1):105–19.CrossRefPubMedGoogle Scholar
  60. 60.
    Lentine KL, Costa SP, Weir MR, Robb JF, Fleisher LA, Kasiske BL, et al. Cardiac disease evaluation and management among kidney and liver transplantation candidates. Circulation. 2012;126(5):617–63.CrossRefPubMedGoogle Scholar
  61. 61.
    Murray KF, Carithers RL. AASLD practice guidelines: evaluation of the patient for liver transplantation. Hepatology. 2005;41(6):1407–32.CrossRefPubMedGoogle Scholar
  62. 62.
    Krowka MJ, Plevak DJ, Findlay JY, Rosen CB, Wiesner RH, Krom RA. Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transpl. 2000;6(4):443–50.CrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    Robalino BD, Moodie DS. Association between primary pulmonary hypertension and portal hypertension: analysis of its pathophysiology and clinical, laboratory and hemodynamic manifestations. J Am Coll Cardiol. 1991;17(2):492–8.CrossRefPubMedGoogle Scholar
  64. 64.
    Ashfaq M, Chinnakotla S, Rogers L, Ausloos K, Saadeh S, Klintmalm G, et al. The impact of treatment of portopulmonary hypertension on survival following liver transplantation. Am J Transplant. 2007;7(5):1258–64.CrossRefPubMedGoogle Scholar
  65. 65.
    Austin MJ, McDougall NI, Wendon JA, Sizer E, Knisely AS, Rela M, et al. Safety and efficacy of combined use of sildenafil, bosentan, and iloprost before and after liver transplantation in severe portopulmonary hypertension. Liver Transpl. 2008;14(3):287–91.CrossRefPubMedGoogle Scholar
  66. 66.
    Plotkin JS, Kuo PC, Rubin LJ, Gaine S, Howell CD, Laurin J, et al. Successful use of chronic epoprostenol as a bridge to liver transplantation in severe portopulmonary hypertension1. Transplantation. 1998;65(4):457–9.CrossRefPubMedGoogle Scholar
  67. 67.
    Raevens S, De Pauw M, Reyntjens K, Geerts A, Verhelst X, Berrevoet F, et al. Oral vasodilator therapy in patients with moderate to severe portopulmonary hypertension as a bridge to liver transplantation. Eur J Gastroenterol Hepatol. 2013;25(4):495–502.CrossRefPubMedGoogle Scholar
  68. 68.
    Ghofrani H-A, Galiè N, Grimminger F, Grünig E, Humbert M, Jing Z-C, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013;369(4):330–40.CrossRefPubMedPubMedCentralGoogle Scholar
  69. 69.
    Savale L, Magnier R, Le Pavec J, Jaïs X, Montani D, O’Callaghan DS, et al. Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension. Eur Respir J. 2013;41(1):96–103.CrossRefPubMedGoogle Scholar
  70. 70.
    Galiè N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, et al. Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies (ARIES) Group. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008;117(23):3010–9.CrossRefGoogle Scholar
  71. 71.
    Pulido T, Adzerikho I, Channick RN, Delcroix M, Galiè N, Ghofrani H-A, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369(9):809–18.CrossRefGoogle Scholar
  72. 72.
    Tuder RM, Cool CD, Geraci MW, Wang J, Abman SH, Wright L, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med. 1999;159(6):1925–32.CrossRefPubMedPubMedCentralGoogle Scholar
  73. 73.
    Sakai T, Planinsic RM, Mathier MA, de Vera ME, Venkataramanan R. Initial experience using continuous intravenous treprostinil to manage pulmonary arterial hypertension in patients with end-stage liver disease. Transpl Int. 2009;22(5):554–61.CrossRefPubMedGoogle Scholar
  74. 74.
    Provencher S, Herve P, Jais X, Lebrec D, Humbert M, Simonneau G, et al. Deleterious effects of β-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. Gastroenterology. 2006;130(1):120–6.CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    Fallon MB, Krowka MJ, Brown RS, Trotter JF, Zacks S, Roberts KE, et al. Impact of hepatopulmonary syndrome on quality of life and survival in liver transplant candidates. Gastroenterology. 2008;135(4):1168–75.CrossRefPubMedPubMedCentralGoogle Scholar
  76. 76.
    Fallon MB, Abrams GA. Pulmonary dysfunction in chronic liver disease. Hepatology. 2000;32(4):859–65.CrossRefPubMedGoogle Scholar
  77. 77.
    Schenk P, Schöniger-Hekele M, Fuhrmann V, Madl C, Silberhumer G, Müller C. Prognostic significance of the hepatopulmonary syndrome in patients with cirrhosis. Gastroenterology. 2003;125(4):1042–52.CrossRefPubMedGoogle Scholar
  78. 78.
    Katsuta Y, Honma H, Zhang X-J, Ohsuga M, Komeichi H, Shimizu S, et al. Pulmonary blood transit time and impaired arterial oxygenation in patients with chronic liver disease. J Gastroenterol. 2005;40(1):57–63.CrossRefPubMedGoogle Scholar
  79. 79.
    Carter EP, Sato K, Morio Y, McMurtry IF. Inhibition of K Ca channels restores blunted hypoxic pulmonary vasoconstriction in rats with cirrhosis. Am J Physiol Lung Cell Mol Physiol. 2000;279(5):L903–10.CrossRefPubMedGoogle Scholar
  80. 80.
    Abrams GA, Jaffe CC, Hoffer PB, Binder HJ, Fallon MB. Diagnostic utility of contrast echocardiography and lung perfusion scan in patients with hepatopulmonary syndrome. Gastroenterology. 1995;109(4):1283–8.CrossRefPubMedPubMedCentralGoogle Scholar
  81. 81.
    Lange PA, Stoller JK. The hepatopulmonary syndrome. Ann Intern Med. 1995;122(7):521–9.CrossRefPubMedGoogle Scholar
  82. 82.
    Gupta S, Castel H, Rao R, Picard M, Lilly L, Faughnan M, et al. Improved survival after liver transplantation in patients with hepatopulmonary syndrome. Am J Transplant. 2010;10(2):354–63.CrossRefGoogle Scholar
  83. 83.
    Matsumori A, Ohashi N, Hasegawa K, Sasayama S, Eto T, Imaizumi T, et al. Hepatitis C virus infection and heart diseases. Jpn Circ J. 1998;62(5):389–91.CrossRefPubMedGoogle Scholar
  84. 84.
    Poller W, Kaya Z, Muche M, Kasner M, Skurk C, Kappert K, et al. High incidence of cardiac dysfunction and response to antiviral treatment in patients with chronic hepatitis C virus infection. Clin Res Cardiol. 2017;106(7):551–6.CrossRefPubMedGoogle Scholar
  85. 85.
    Terrier B, Karras A, Cluzel P, Collet J-P, Sène D, Saadoun D, et al. Presentation and prognosis of cardiac involvement in hepatitis C virus-related vasculitis. Am J Cardiol. 2013;111(2):265–72.CrossRefPubMedGoogle Scholar
  86. 86.
    Longo M, Crosignani A, Battezzati P, Giussani CS, Invernizzi P, Zuin M, et al. Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis. Gut. 2002;51(2):265–9.CrossRefPubMedPubMedCentralGoogle Scholar
  87. 87.
    Propst A, Propst T, Lechleitner M, Hoppichler F, Kathrein H, Vogel W, et al. Hypercholesterolemia in primary biliary cirrhosis is no risk factor for atherosclerosis. Dig Dis Sci. 1993;38(2):379–80.CrossRefPubMedGoogle Scholar
  88. 88.
    Floreani A, Variola A, Niro G, Premoli A, Baldo V, Gambino R, et al. Plasma adiponectin levels in primary biliary cirrhosis: a novel perspective for link between hypercholesterolemia and protection against atherosclerosis. Am J Gastroenterol. 2008;103(8):1959.CrossRefPubMedGoogle Scholar
  89. 89.
    Keresztes K, Istenes I, Folhoffer A, Lakatos PL, Horvath A, Csak T, et al. Autonomic and sensory nerve dysfunction in primary biliary cirrhosis. World J Gastroenterol. 2004;10(20):3039.CrossRefPubMedPubMedCentralGoogle Scholar
  90. 90.
    Agelopoulou P, Kapatais A, Varounis C, Grassos C, Kalkandi E, Kouris N, et al. Hepatocellular carcinoma with invasion into the right atrium. Report of two cases and review of the literature. Hepato-Gastroenterology. 2006;54(79):2106–8.Google Scholar
  91. 91.
    Lin TY, Chiu KM, Chien CY, Wang MJ, Chu SH. Unusual sites of metastatic involvement: case 1. Right ventricular outflow obstruction caused by metastatic hepatocellular carcinoma. J Clin Oncol. 2004;22(6):1152–3.CrossRefPubMedGoogle Scholar
  92. 92.
    Oncale M, Lewis B. Hepatocellular carcinoma with extension to the heart via the inferior vena cava. Proc (Bayl Univ Med Cent). 2015;28(2):229.CrossRefGoogle Scholar
  93. 93.
    Hayashi N, Yasunori H, Soma I, Fukuchi N, Izawa H, Yoshida T, et al. Non-surgical treatment of hepatocellular carcinoma with tumor thrombus in the right atrium. Gan To Kagaku Ryoho. 2004;31(11):1918–20.PubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Ana-Maria Vintilă
    • 1
  • Monica Dobrovie
    • 2
  • Vlad Damian Vintilă
    • 3
  1. 1.Department of Internal MedicineColţea Clinical Hospital, “Carol Davila” University of Medicine and PharmacyBucharestRomania
  2. 2.Department of Internal MedicineColţea Clinical HospitalBucharestRomania
  3. 3.Department of CardiologyUniversity Emergency Hospital, “Carol Davila” University of Medicine and PharmacyBucharestRomania

Personalised recommendations